CTS successfully implemented Donor-Screen HLA® Class I and II testing on the Stratec Biomedical AG Gemini on Monday, April 29th. As previously communicated, the Immucor assay and sample requirements are the same, and the package insert has been modified to state the assay is specific to the Stratec Gemini instrument. The new package insert, assay history list, and platform history list are now available on our website.
The FDA Guidance ZIKV video for the webinar held on 08/15/18 has been posted in the Wh...
We received an updated WNV package insert; please note the manufacturer and license number has been ...
CTS received notification from Sanochemia Pharmazeutika AG of their intent to immediately discontinu...
Reminder - Dr. Buff Mair is the new CTS Medical Director. Several of the CTS client forms specify li...
CTS was recently notified that one of the tubes listed in the Sample Acceptability document...
On April 29, 2019, CTS will begin performing Donor-Screen HLA® Class I and II testing on the Str...